VEGI (Human); VEGI-192
- 产品详情
- 实验流程
Species | Human |
---|---|
Sequence | The sequence of the first five N-terminal amino acids has been found to be Met-Gln-Leu-Thr-Lys. |
Purity | The purity of Recombinant Human VEGI-192 is greater than 95.0%, as determined by the following methods: (a) RP-HPLC analysis (b) Reducing and non-reducing SDS-PAGE silver-stained gel analysis |
Endotoxin Level | The endotoxin level of Recombinant Human VEGI-192 is below 0.1 ng/µg (1 IEU/µg) of rHuVEGI. |
Formulation | Recombinant Human VEGI-192 is lyophilized after extensive dialysis against 0.5 M NaCl, 50 mM Tris-HCl buffer, pH 7.5. |
Reconstitution | It is recommended that the lyophilized VEGI-192 be reconstituted in sterile 18 MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. |
Target Background | Vascular endothelial growth inhibitor (VEGI; TNFSF-15) is a new member of the tumor necrosis factor family. VEGI is predominantly an endothelial cell-specific gene, and recombinant VEGI is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. VEGI exerts two activities on endothelial cells: early G1 arrest of G0/G1-cells responding to growth stimuli, and programmed death of proliferating cells. These activities are highly specific to endothelial cells. VEGI is also able to regulate the expression of several important genes involved in angiogenesis. These findings are consistent with the view that VEGI functions as an autocrine cytokine to inhibit angiogenesis and stabilize the vasculature. Vascular Endothelial Growth Inhibitor (VEGI), human, produced in E. coli, is a single, non-glycosylated polypeptide chain containing 192 amino acids and having a molecular mass of 21,858 Da. |
---|
Research Areas
For Research Use Only. Not For Use In Diagnostic Procedures.
Application Protocols
Provided below are standard protocols that you may find useful for product applications.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.